Scandinavian ChemoTech: Weathering the storm - Redeye

Redeye provides a research update on Scandinavian ChemoTech following the Q4 2023 report and the retracted sales target in India. The company delivered a quarterly report that fell short of Redeye's estimates. Sales came in lower than anticipated, and OPEX was slightly higher, most likely due to some one-off items. On the positive note, a fifth commercial installation has been carried out on the US market and a TAM-expanding amendment to the study protocol at AIIMS Jodhpur has been announced.

Länk till analysen i sin helhet: https://www.redeye.se/research/970138/scandinavian-chemotech-weathering-the-storm?utm_source=finwire&utm_medium=RSS